EGFR and breast carcinoma: In the current study, we found that the expression of ZNF516 is progressively lost during breast cancer progression, and, consistent with our observation that ZNF516 transcriptionally represses EGFR, we showed that the level of ZNF516 expression is negatively correlated with that of EGFR.